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The identification of germline mutations in families with HNPCC is hampered by genetic heterogeneity and clinical
variability. In previous studies, MSH2 and MLH1 mutations were found in approximately two-thirds of the Am-
sterdam-criteria–positive families and inmuch lower percentages of the Amsterdam-criteria–negative families.There-
fore, a considerable proportion of HNPCC seems not to be accounted for by the major mismatch repair (MMR)
genes. Does the latter result from a lack of sensitivity of mutation detection techniques, or do additional genes
underlie the remaining cases? In this study we address these questions by thoroughly investigating a cohort of
clinically selected North American families with HNPCC. We analyzed 59 clinically well-defined U.S. families with
HNPCC for MSH2, MLH1, and MSH6 mutations. To maximize mutation detection, different techniques were
employed, including denaturing gradient gel electrophoresis, Southern analysis, microsatellite instability, immuno-
histochemistry, and monoallelic expression analysis. In 45 (92%) of the 49 Amsterdam-criteria–positive families
and in 7 (70%) of the 10 Amsterdam-criteria–negative families, a mutation was detected in one of the three analyzed
MMR genes. Forty-nine mutations were in MSH2 or MLH1, and only three were in MSH6. A considerable
proportion (27%) of the mutations were genomic rearrangements (12 inMSH2 and 2 inMLH1). Notably, a deletion
encompassing exons 1–6 of MSH2 was detected in seven apparently unrelated families (12% of the total cohort)
and was subsequently proven to be a founder. Screening of a second U.S. cohort with HNPCC from Ohio allowed
the identification of two additional kindreds with the identical founder deletion. In the present study, we show that
optimal mutation detection in HNPCC is achieved by combining accurate and expert clinical selection with an
extensive mutation detection strategy. Notably, we identified a common North American deletion in MSH2, ac-
counting for ∼10% of our cohort. Genealogical, molecular, and haplotype studies showed that this deletion rep-
resents a North American founder mutation that could be traced back to the 19th century.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC
[MIM 114500]) is the most frequent autosomal domi-
nant predisposition to the development of colorectal
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cancer. It is caused by germline mutations in human
homologues of the bacterial mismatch repair (MMR)
genes MutL and MutS: MSH2 on chromosome 2p16,
MLH1 on 3p21, MSH6 on 2p15, and PMS1 and PMS2
on 7p22 (Fishel et al. 1993; Bronner et al. 1994; Ni-
colaides et al. 1994; Akiyama et al. 1997; Miyaki et al.
1997). The identification of germline mutations in fam-
ilies with HNPCC and HNPCC-like disease is hampered
not only by this locus heterogeneity but also by the clin-
ical variability among families withHNPCC.Apart from
a lifetime risk of colorectal cancer of ∼80% (Vasen et
al. 1996; Aarnio et al. 1999), individuals with an MMR
gene mutation are characterized by an increased risk of
tumors of the endometrium, stomach, small intestine,
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pancreas, hepatobiliary system, urinary tract, ovary,
brain, and skin (Lynch 1999). The vast majority of
HNPCC-causing mutations have been reported inMSH2
and MLH1 (Peltomaki and Vasen 1997). Accordingly,
mutations in these genes give rise to the “classical”
HNPCC phenotype (Wijnen et al. 1997; Giardiello et
al. 2001), whereasMSH6mutations have been described
in families with more atypical HNPCC (Kolodner et al.
1999; Wijnen et al. 1999; Wu et al. 1999; Wagner et al.
2001). Only a few PMS2 germline mutations have been
described so far (Hamilton et al. 1995; Liu et al. 2001).
Identification of HNPCC-causing MMR gene muta-
tions enables at-risk relatives to be informed about their
cancer risks and to benefit from intensive surveillance
programs that have been proven to reduce their over-
all mortality by 65% (Jarvinen et al. 2000). To opti-
mize mutation analysis in families with HNPCC and
HNPCC-like disease, several clinical criteria have been
formulated. Of these, the Amsterdam criteria, estab-
lished by the International Collaborative Group on
HNPCC (Vasen et al. 1991, 1999), are now recognized
as the gold standard in HNPCC clinical selection. Pre-
viously, MLH1 or MSH2 mutations have been found
in only 45%–64% and 0%–47% of the Amsterdam
criteria–positive and –negative families, respectively
(Giardiello et al. 2001). Since 190% of HNPCC colo-
rectal cancers display microsatellite instability (MSI)
(Aaltonen et al. 1994; Fujiwara et al. 1998), in contrast
to 12%–18% of the sporadic colorectal cancers (Ionov
et al. 1993; Thibodeau et al. 1993), the “Bethesda
guidelines” include MSI as an additional selection tool
for MMR gene mutation analysis (Rodriguez-Bigas et
al. 1997). However, although the application of the Be-
thesda guidelines does improve the mutation analysis
sensitivity, it also results in a remarkable reduction of
its specificity compared with the Amsterdam criteria,
since a considerable number of families with more atyp-
ical phenotypes are included (Syngal et al. 2000). The
value of immunohistochemical (IHC) analysis of MMR
proteins as a valuable additional selective tool has been
shown in several studies (de Leeuw et al. 2000; Lindor
et al. 2002; Hendriks et al. 2003), although positive
IHC staining is observed in the presence of certain mu-
tation types (Wahlenberg et al. 2002).
The fact that germline MSH2 and MLH1 mutations
cannot be identified in a still-considerable proportion
of the families with “classical” HNPCC may be ex-
plained by the involvement of additional HNPCC genes.
MSH6, PMS2, and the more recently described MLH3
and EXO1 genes may represent candidate disease-caus-
ing genes for MSH2- and MLH1-negative families (Wu
et al. 2001a, 2001b). However, preliminary data indi-
cate that germline mutations in these genes are more
likely to either result in atypical HNPCC phenotypes
and are rare in families with “classical”HNPCC (MSH6
and PMS2) or represent only mild genetic modifiers
(EXO1 and MLH3) (Hamilton et al. 1995; Kolodner
et al. 1999; Wijnen et al. 1999; Wu et al. 1999, 2001a,
2001b; Wagner et al. 2001; Jagmohan-Changur et al.
2003). By means of more-sensitive mutation detection
protocols (conversion technology or monoallelic mu-
tation analysis [MAMA]), Yan et al. (2000) showed
involvement ofMSH2 orMLH1 in all the families with
“classical” HNPCC analyzed. This suggested that clin-
ically well-defined HNPCC is caused by MSH2 and
MLH1 alone and that our efforts should be focused on
developing new and/or more-thorough mutation detec-
tion approaches. To this end, we analyzed a cohort of
families with clinically very well defined HNPCC and
HNPCC-like disease from the United States for the pres-
ence of MSH2, MLH1, andMSH6 germline mutations,
by using different techniques to optimize mutation de-
tection. The results presented here not only provide a
comprehensive spectrum of the molecular basis of
HNPCC in the United States but also underscore the
need for clinical selection for a cost-effective screening
of MMR genes.
Patients and Methods
The Henry Lynch HNPCC Cohort
The study included a total of 59 extended families
selected for having conditions reminiscent of HNPCC
by H. Lynch at the Department of Preventive Medicine
and Public Health, Creighton University. The process of
genetic counseling employed in the management of these
families has been described elsewhere (Lynch et al.
1999). Forty-nine families fulfilled the Amsterdam cri-
teria. Of the 10 Amsterdam criteria–negative families, 9
were characterized by two first-degree relatives with an
HNPCC-related tumor (colorectal, endometrial, urinary
tract, or small bowel cancer), with one relative diagnosed
before the age of 50 years. Only one family did not meet
the criteria because of the later (50 years) age at onset
of the HNPCC-related tumors. However, one patient
from this family presented with multiple HNPCC-re-
lated tumors. The majority of the families (80%) en-
compasses five or more generations, whereas, in the re-
maining cases, four generations were recorded. More
family characteristics are listed in table 1. For each fam-
ily, the youngest affected relative available was selected
for mutation analysis, with only three exceptions: in two
families, only a single relative with colorectal carcinoma
in situ was available for mutation analysis; in a third
one, only a nonpenetrant individual was available. Of
the selected probands, 24 had colorectal cancer diag-
nosed before the age of 50 years (and 17 at the age of
45 years or younger). Eight probands had endometrial
cancer (six diagnosed before the age of 50 years), and
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Table 1
Clinical Features of the 59 Families with HNPCC Studied in this Article
Colorectal
Cancer
Endometrial
Cancer
Other
HNPCC-Related
Tumorsa
Mean no. per family 7.4 1.9 2.1
Mean age at onset, in years (range) 45.2 (19–85) 46.4 (31–77) 52.8 (27–76)
a Ovary cancer, stomach cancer, urinary tract cancer, and small-bowel cancer.
one had small bowel cancer at age 29 years. Twenty-
three probands had multiple HNPCC-related tumors
(including sebaceous adenomas).
Eleven families with HNPCC selected for this study
and screened only for the founder mutation were di-
agnosed at the Ohio State University’s James Cancer
Hospital, Columbus, Ohio. Among these, five were Am-
sterdam-positive and, in the remaining six families, there
were features highly suggestive of HNPCC, including
early onset and/or multiple primary cancers in the pro-
band, one or two first-degree relatives with endometrial
cancer, or multiple second-degree relatives with colorec-
tal or endometrial cancer. An additional cohort of 128
patients with colorectal ( ) or endometrial (np 85 np
) cancer from Ohio was studied. These patients rep-43
resented all MSI-positive cases (98 MSI-high and 30
MSI-low) from a cohort of 716 unselected, consecutive,
newly diagnosed patients with colorectal ( ) ornp 482
endometrial ( ) cancer in the Columbus area,np 234
collected in 1998–2000.
Denaturing Gradient Gel Electrophoresis (DGGE)
DNA from at least one affected relative of every kin-
dred was analyzed. Genomic DNA was obtained from
peripheral blood lymphocytes. Initial DNA analysis was
performed by DGGE and direct sequencing, as described
elsewhere (Wijnen et al. 1998b, 1999). In short,MSH2-
and MLH1-specific exons were amplified by PCR and
were analyzed by GC-clamped DGGE. Exons with al-
tered patterns of migration on DGGE were sequenced,
to determine the nucleotide alteration. MSH6 was an-
alyzed by DGGE in families negative for pathogenic mu-
tations in MSH2 or MLH1.
Southern Blot Analysis
Southern analysis of MSH2, MLH1, and MSH6 was
performed in the families negative for a pathogenic point
mutation after DGGE analysis, according to our pre-
viously established protocol (Wijnen et al. 1998a). Anal-
ysis of MSH2 was performed with XbaI, HindIII, NsiI,
and EcoRI genomic DNA digests, followed by hybrid-
ization with three overlapping cDNA probes (encom-
passing exons 1–7, exons 7–12, and exons 10–16). Anal-
ysis of MLH1 was performed with XbaI, ApaI, HindIII,
and NsiI digests hybridized with two specific cDNA
probes encompassing exons 1–12 and exons 11–19;
MSH6 Southern analysis was performed with XbaI and
ApaI digests, followed by hybridization with two cDNA
probes encompassing exons 1–4 and exons 5–10.
Characterization of the Founder Deletion in MSH2
Molecular Analysis.—An apparently identical dele-
tion encompassing exons 1–6 of the MSH2 gene was
identified by Southern analysis in seven apparently un-
related families. Primers were designed around the ap-
proximate location of breakpoints inferred from the
restriction map of the deleted chromosome. The 3′
primer (F3) was located in intron 6 of the MSH2 gene
(5′-AAGCATCACAGTTACTGTTG-3′), whereas the 5′
primer (R3) was derived on the basis of genomic se-
quences ∼2 kb upstream of exon 1 (5′-GCTGAATTAG-
GTTTTGGAAC-3′). Through use of these primers, a
deletion-specific PCR product of ∼1,700 bp was ob-
tained by long range PCR (Roche Molecular Biochem-
icals). This product was partly sequenced using a third
primer (R2) located ∼1 kb upstream of exon 1 (5′-
TTTCAATCTGTCGCCCACGC-3′). These primers
were also employed to screen two Ohio cohorts.
Genealogical Studies.—Genealogical data were ob-
tained from the records of the Mormon Church (Fam-
ilySearch Internet Web site) and the Offices of Vital Sta-
tistics, as well as from cemeteries’ records and patient
recollection.
Haplotype Analysis.—To determine the genetic history
of the deletion chromosome, chromosome 2 haplotypes
were derived from several affected and unaffected indi-
viduals by PCR amplification of CA repeat markers prox-
imal and distal to the MSH2 gene. The employed chro-
mosome 2markers were as follows: tel-D2S119-D2S288-
D2S391-MSH2IVS1012gra-CA1-D2S123-D2S378-cen.
Primers and PCR conditions were as described elsewhere
(Gyapay et al. 1994; Wijnen et al. 1994; Hutter et al.
2000). Also, amonochromosomal somatic cell hybrid (see
below), containing the founder exon 1–6 deletion, was
derived from Ohio family 726NM, to facilitate the study
of the haplotype of the mutation-carrying chromosome.
MSI, IHC, and MAMA
MSI and IHC analysis was performed on tumor sam-
ples from one index patient negative forMSH2, MLH1,
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Table 2
Summary of Results of the Point Mutation Analysis in Our
Cohort
GENE AND
MUTATION TYPE
NO. OF POINT
MUTATIONS INa
TOTAL
( )Np 59
AC-Positive
Families
( )Np 49
AC-Negative
Families
( )Np 10
MLH1:
Frameshift 8 0 8
Nonsense 2 1 3
Splice site 6 2 8
Missense 3 1 4
Subtotal 19 4 23
MSH2:
Frameshift 4 0 4
Nonsense 3 1 4
Splice site 1 0 1
Missense 1 1b 2
Subtotal 9 2 11
MSH6:
Frameshift 1 0 1
In-frame deletion 0 1 1
Missense 1 0 1
Subtotal 2 1 3
Total 30 7 37
NOTE.—In case of double mutations, only the assumed disease-
causing mutation is reported.
a AC p Amsterdam criteria.
b A636P in MSH2, a pathogenic Ashkenazi Jewish founder
mutation (Yuan et al. 1999; Foulkes et al. 2002).
or MSH6 mutation (family 101), as well as from one
index patient (family 125) with a missense mutation in
MSH2. MSI analysis was performed with the National
Cancer Institute–recommended markers (Boland et al.
1998), complemented by markers BAT40, MSH3, and
MSH6 (Hendriks et al. 2003). IHC was performed with
antibodies against MSH2, MLH1, and MSH6, as de-
scribed elsewhere (de Leeuw et al. 2000). MSI status in
the Ohio cohorts was determined with the NCI-rec-
ommended markers. Both MSI-high and -low cases were
included.
We have applied MAMA of the alleged mutated allele
isolated in a murine background (Papadopoulos et al.
1995; Yan et al. 2000). However, because of the limited
availability of appropriate patient material from the 59
families with HNPCC, only few selected cases were an-
alyzed by MAMA, mainly to provide proof of feasibility
for this technical approach: the paracentric chromosome
2p inversion (family 140) (Wagner et al. 2002), a de-
letion of exons 1–13 of MLH1 (family 103), and one
family negative for mutations in MSH2, MLH1, or
MSH6 (family 143). In brief, somatic cell hybrids con-
taining only one chromosome 2p or 3p allele from the
index patient were generated by fusing peripheral blood
lymphocytes or lymphoblastoid cell lines within an
Msh2-deficient murine epithelial cell line (GMP Con-
version Technologies) (Papadopoulos et al. 1995; Yan
et al. 2000). Somatic cell hybrids were genotyped by CA
repeat markers around the MSH2 and MLH1 genes on
chromosomes 2p and 3p, respectively, and were selected
for MAMA. Total RNA and protein samples were iso-
lated from the different hybrid cell lines. RT-PCR using
random hexamers (Fermentas) was performed, followed
by a standard PCR using human-specific primers for
MSH2 (forward primer 5′-ATATCATGGAACCAGCA-
3′ and reverse primer 5′-TACCTTCATTCCATTACT-
GG-3′), MLH1 (forward primer 5-GCCATTGTCACA-
GAGGATAA-3′ and reverse primer 5′-CGAAGGAGTG-
GTTAAGCAAC-3′) and MSH6 (forward primer 5′-T-
CGGTAGCGCCTGCTGCCCC-3′ and reverse primer
5′-TAAGTTGTGCCTACCTCCA-3′). In addition, west-
ern blot analysis was performed on protein lysates ob-
tained from the somatic cell hybrid lines through use of
a rabbit polyclonal antibody raised against amino acids
402–737 of human MSH2 (Smits et al. 2000).
Results
Point-Mutation Analysis
A total of 37 germline mutations was detected in
MSH2, MLH1, andMSH6 by DGGE analysis, including
seven mutations of uncertain pathologic significance (six
missense mutations and one in-frame 3-nt deletion) (ta-
ble 2). In another three families, both a missense and a
pathogenic mutation were detected (table 3). Most point
mutations (23 of 37) were detected in MLH1. In three
independent families, an identical nonsense mutation in
MLH1 exon 12 leading to exon skipping was found
(Stella et al. 2001).
Detection of Genomic Rearrangements
Southern blot analysis was performed in 29 of the 59
families with HNPCC, where no pathogenic point mu-
tation was found. In total, 14 genomic rearrangements
were detected, 12 in MSH2 and 2 in MLH1 (table 4).
One of the deletions is a13-kb deletion 6 kb upstream
ofMSH2 (family 177). All families with a rearrangement
of MSH2 or MLH1 fulfilled the Amsterdam criteria. In
seven families, an identical deletion of exons 1–6 of the
MSH2 gene was identified. The further characterization
of this deletion is described below. Other deletions and
types of rearrangement were also observed in theMSH2
gene: a second but different deletion of at least 20 kb
encompassing exons 1–6 (family 108), an ∼2-kb exon
3 deletion (family 150), and a deletion of exons 3–8 of
∼50 kb (family 136). The chromosome 2 paracentric
inversion encompassingMSH2 exons 8–16 found in one
kindred (family 140) has been reported elsewhere (Wag-
ner et al. 2002). In MLH1, two genomic deletions, en-
Table 3
Overview of the Individual Probands and Mutations Detected in the 59
Families
FAMILY ACa
MUTATION IN
MSH2 MLH1 MSH6
101 
102  243delAATG
103  D exons 1–13 and E578G
104  G67R
107  IVS53art
108  D exons 1–6
109  733insAACA
110  IVS51grc
111  840delA
112  A29S
113  466delC
114 
115  A636P
116  N583S IVS71grt
117  Q298X
118  K461X
119  64insA
120  D exon 6
121  IVS62arg
122  D exons 1–6b
123  D exons 1–6b
124  D exons 1–6b
125  T552P
126  129delTC and S473L
127  R226L (splice site)
128  52insA
129  V185L
130  D exons 1–6b
131  55delC
132  IVS181gra
133 K461X
134  IVS62arg
135  K461X
136  D exons 3–8
137  733insAACA
138  Q885X
139  IVS131grt
140  inv exons 8–16
141  R389X
142  IVS91gra
143 
145  168insA
146 
147 
148  D exons 1–6b
149  806insA
150  D exon 3
151 
152  D exons 1–6b
153  1087insC
154  1013delCTT
155  D exons 1–6b
157  R680X
158  IVS33trg
177  D 5′ MSH2
178  G244D
205  525delTT
207 
208  M492V
NOTE.—D p deletion.
a AC p Amsterdam criteria.
b Founder genomic deletion encompassing exons 1–6 of the MSH2 gene.
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Table 4
Summary of Genomic Rearrangements in the 59 Families
with HNPCC
FAMILY
GENOMIC REARRANGEMENT IN
MSH2 MLH1
103 Deletion of exons 1–13
108 Deletion of exons 1–6
120 Deletion of exon 6
122 Deletion of exons 1–6a
123 Deletion of exons 1–6a
124 Deletion of exons 1–6a
130 Deletion of exons 1–6a
136 Deletion of exons 3–8
140 Inversion of exons 8–16
148 Deletion of exons 1–6a
150 Deletion of exon 3
152 Deletion of exons 1–6a
155 Deletion of exons 1–6a
177 Upstream deletionb
Total 12 2
a The founder genomic deletion encompassing exons 1–6 of
the MSH2 gene.
b An ∼13-kb deletion, the 3′ breakpoint end of which maps
6 kb 5′ of MSH2. The pathogenicity of this deletion could not
be investigated.
Table 5
Overview of the Results of the Complete Mutation Analysis of the
MSH2, MLH1, and MSH6 Genes in the 59 Families with HNPCC
GENE AND MUTATION TYPE
NO. OF MUTATIONS IN
TOTAL
( )Np 59
AC-Positive
Families
( )Np 49
AC-Negative
Families
( )Np 10
MLH1:
Point mutation 19 4 23
Genomic deletion 2 0 2
Subtotal 21 4 25 (42%)
MSH2:
Point mutation 10a 2 12
Genomic deletion/inversion 12 0 12
Subtotal 22 2 24 (41%)
MSH6:
Point mutation 2 0 2
In-frame deletion 0 1 1
Subtotal 2 1 3 (5%)
Total 45 (92%) 7 (70%) 52 (88%)
NOTE.—In the case of double mutations, only the assumed disease-
causing mutation is reported.
a Including the splice-site mutation detected by MAMA analysis by
Yan et al. (2000).
compassing exon 6 (∼2.3 kb; family 120) and exons
1–13 (at least 42 kb; family 103), were identified. No
MSH6 genomic rearrangements were found among the
29 families (tables 4 and 5).
Characterization of the MSH2 Exon 1–6 Founder
Deletion
Molecular Analysis.—In seven patients, aberrant frag-
ments of ∼14 kb were apparent by Southern analysis
after digestion with EcoRI and hybridization with the
MSH2 exon 7 probe (fig. 1a). Also, on the basis of de-
creased intensity of the wild-type fragment and addi-
tional hybridizations with exon 1–6 probes (data not
shown), the presence of the aberrant EcoRI fragment
was indicative of a genomic deletion of exons 1–6 of
the MSH2 gene. Digestion by BclI revealed an ∼13-kb
aberrant fragment and confirmed the presence of an
identical rearrangement in these seven families. To fur-
ther characterize this recurring North American deletion
previously not found among HNPCC samples of Eu-
ropean origin (Wijnen et al. 1998a), PCR primers were
designed around the approximate location of break-
points inferred from the restriction map of the deleted
chromosome. The 5′ primer (R3) was based on genomic
sequences ∼2 kb upstream of exon 1, whereas the 3′
primer (F3) was located in intron 6 of the MSH2 gene.
Long range PCR with these primers resulted in a dele-
tion-specific PCR product of ∼1,700 bp, exclusively ob-
served in carriers of the common deletion and not in
deletion-negative controls (data not shown). Sequencing
of the breakpoint revealed exactly the same nucleotide
sequence in all seven families diagnosed with the exon
1–6 deletion by Southern analysis. The breakpoints are
positioned within two Alu repeats (fig. 1B and 1C).
Thus, the deletion is likely to have arisen through an
Alu-mediated recombination. The presence of identical
breakpoint sequences in all seven cases is suggestive of
a founder mutation, since a frequently recurring recom-
bination event would be likely to result in at least a few
single-nucleotide differences.
Screening for the Founder Deletion.—An additional
cohort of 11 clinically selected families with HNPCC
from Ohio was investigated for the presence of the com-
mon deletion, through use of the PCR primers (R3 and
F3) described above. Two additional deletions were de-
tected (families 726NM and CG336). Notably, the same
mutation was not found in a consecutive series (np
) of newly diagnosed MSI-positive patients with128
colorectal and endometrial cancer derived from a total
of 716 Ohio patients studied for MSI.
Haplotype Analysis.—To confirm the common genetic
origin of the deletion of exons 1–6, haplotype analysis
was performed (fig. 2). With the exception of families
124 and CG336, the haplotype of the deleted allele was
reconstructed in the seven remaining families, six from
the Lynch cohort and one of the two Ohio kindreds
(726NM) found to carry the identical MSH2 deletion.
A common haplotype is evident in all families, with the
one exception of kindred 155, which shows, possibly as
the result of mitotic recombination, novel alleles at
markers DS288 and D2S119. Additional variation was
Figure 1 A, Southern blot analysis of genomic DNA samples from North American individuals with HNPCC, revealing a common rear-
rangement. Total genomic DNA was digested with EcoRI and was hybridized with the MSH2 exon 7–specific probe. An aberrant ∼14-kb band
was observed in lanes 7, 8, 9, 10, 14, 17, and 18, corresponding to individuals from families 122, 123, 124, 130, 148, 152, and 155, respectively.
Aberrant fragments of different sizes are also observed in lanes 4 (family 108, carrying a similar but distinct MSH2 exon 1–6 deletion) and 20 (a
previously identified carrier of an MSH2 exon 6 deletion, employed here as positive control). Also note that the presence of additional bands is
accompanied by a decreased intensity of the ∼9-kb wild-type fragments encompassing exon 7. The latter was confirmed by hybridizations with
exon 1–6 probes and by BclI digestion (data not shown). B, Genomic map of the normal and deleted MSH2 gene. For the sake of clarity, only the
EcoRI restriction sites, the Alu repeats involved in the recombination (shaded boxes), and the relevantMSH2 exons (blackened boxes) are depicted.
The normal (∼9-kb) and aberrant (∼14-kb) EcoRI restriction fragments also shown in panel A are indicated, as well as the primers (R3, R2, and
F3) employed to selectively amplify the deletion breakpoint by PCR. C, Nucleotide sequence of the founder deletion breakpoint. Three distinct
sequences are reported from top to bottom: the normal sequence flanking MSH2 at the 5′ side, the deletion breakpoint, and the normal sequence
of MSH2 intron 6. The shaded boxes indicate the nucleotide homology between the two Alu repeats present in the 5′ flanking sequence and within
intron 6 of MSH2. Because of the extensive homology, it is difficult to pinpoint the exact deletion breakpoint. The arrow indicates its most likely
position on the basis of nucleotide homology.
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Figure 2 Haplotype analysis of the founder MSH2 deletion chromosome. A total of seven polymorphic markers flanking MSH2 on both
the telomeric and centromeric side were employed. The haplotype encompassing the founder MSH2 deletion could be reconstructed in most
families, with the exception of family 124 from the Lynch cohort and kindred CG336 from the Ohio cohort, because of a lack of samples from
informative relatives. The haplotype of family 726NM was derived from a somatic cell hybrid containing the isolated deletion chromosome in
a rodent background. Shaded boxes indicate the alleged founder haplotype. Both alleles are indicated in those cases where the exact phase
could not be derived.
observed exclusively at more-distant centromeric mark-
ers—that is, D2S123 and D2S378 (fig. 2).
Genealogical Studies.—By means of genealogical
studies, a common ancestry could be traced for five of
the nine families found to carry the MSH2 exon 1–6
founder deletion. The alleged ancestor was born around
1814 in Alabama and was presumably of German origin.
He married and became a Mormon. From Alabama, he
and his family undertook a long journey to Utah, fol-
lowing the Mississippi River through Kentucky andMis-
souri. Some family members moved to southeastern
Iowa, bordering Illinois, and then followed the Missouri
River to Nebraska and Wyoming, eventually settling in
Utah. However, the ancestor was excommunicated from
the Mormon Church and moved, with an unspecified
number of children, to California. Two of the families
studied here (122 and 152) still carry the same ancestral
name and live in California. The other families reside
along the trail of their ancestors (A.B., A.W., P.F.F., S.C.,
Y.K., P.W., R.O., J.F.L., R.F., A.D., and H.T.L., unpub-
lished data).
Alternative Approaches to Unresolved Cases
Even when applying the most thorough mutation de-
tection strategy, unresolved cases—that is, mutation-
negative samples or missense mutations of unknown
pathogenic relevance—require additional analyses for
their elucidation. In our study, we were confronted with
a number of such cases. Unfortunately, the limited avail-
ability of blood or tumor samples hampered the appli-
cation of additional approaches to some cases. However,
a number of cases provided proof of feasibility for the
general strategy (table 6).
In one of the families negative for MSH2, MLH1, or
MSH6 mutations (family 101), analysis of the corre-
sponding colorectal cancer revealed an MSI-high phe-
notype and no expression of MSH2 by immunohisto-
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Table 6
Families with Mutations of Unknown Significance and Families without Mutations
FAMILY ACa MUTATION
TEST RESULTb
MSI IHC MAMA
101  High Decreased expression MSH2 NP
104  G67R MLH1 NP NP NP
112  A29S MLH1 NP NP NP
114  NP NP NP
125  T552P MSH2 High Normal expression MSH2, MLH1, MSH6 NP
129  V185L MLH1 NP NP NP
143  NP NP Normal expression MSH2, MLH1, MSH6
146  NP NP NP
147  NP NP NP
151  NP NP NP
154  1013delCTT MSH6 NP NP NP
177  D 5′ MSH2 NP NP NP
178  G244D MLH1 NP NP NP
207  NP NP NP
208  M492V MSH6 NP NP NP
a AC p Amsterdam criteria.
b NP p not performed.
chemistry. This kindred was characterized by a classical
clinical HNPCC phenotype that is likely the result of a
genetic defect in the MSH2 gene that was missed by the
DGGE and Southern approaches. In one other individual
found to carry anMSH2missense mutation of unknown
pathogenic relevance (family 125), analysis of tumor
DNA again revealed an MSI-high phenotype. IHC anal-
ysis of the corresponding tumor sections showed normal
expression of MSH2, MLH1, and MSH6. Although it
is possible that the mutant MSH2 proteins are func-
tionally hampered by the missense mutations, at present
we cannot determine the pathogenicity of this mutation
(Wahlenberg et al. 2002).
MAMA, or conversion technology, represents a useful
and promising approach for the analysis of missense
mutations in MSH2 (Papadopoulos et al. 1995; Yan et
al. 2000). It has also proven to be a useful tool in the
analysis of both splicing errors and genomic alterations
(Nakagawa et al. 2002). Somatic cell hybrids containing
the alleged mutated chromosome in a murine back-
ground can be analyzed by RT-PCR, northern, or west-
ern analysis, to ensure expression and stability of the
human MSH2 gene. We demonstrated proof of feasi-
bility for this approach in the analysis of the pathoge-
nicity of the chromosome 2p paracentric inversion (Wag-
ner et al. 2002). Moreover, the chromosome 3 allele
harboring the MLH1 deletion of exons 1–13 (family
103) did not show any expression of this gene by RT-
PCR after conversion (not shown). Conversion analysis
of the chromosome 2 and 3 alleles of the index patient
negative for mutations in MSH2, MLH1, and MSH6
(family 143) displayed expression of the same genes by
RT-PCR and western blot analysis of the somatic cell
hybrids.
Discussion
The overall mutation detection rate in our study is re-
markably high, compared with most previous studies
(Giardiello et al. 2001). In 39 (80%) of 49 families ful-
filling the Amsterdam criteria, and in 5 (50%) of the 10
Amsterdam criteria–negative families, a pathogenic mu-
tation was found in one of the three MMR genes ana-
lyzed. When the mutations of uncertain significance (ta-
ble 6) are included, the detection percentages rise to 92%
(45 of 49) and 70% (7 of 10) for Amsterdam-positive
and -negative families, respectively (table 5). These re-
sults are supportive of the extremely high MSH2 and
MLH1 mutation detection rate among clinically well-
selected HNPCC families. It is safe to assume that ex-
tension of the MAMA analysis to all the 59 index pa-
tients, improvement of the DGGE strategy, and further
functional analysis of the nucleotide variants of as-yet-
uncertain pathogenic significance would increase detec-
tion rate to close to 95%.
Apart from the more straightforward nonsense and
deletion mutations that are expected to be disease-caus-
ing by nature, several missense mutations were detected
in this study. One of these, the A636P mutation in
MSH2, is a founder mutation in the Ashkenazi Jewish
population and was proven to be pathogenic (Yuan et
al. 1999; Foulkes et al. 2002). Two other missense mu-
tations (G67R and V185L in MLH; families 104 and
129, respectively) were previously described to affect
mismatch repair (Shimodaira et al. 1998; Ellison et al.
2001). In one index patient found to carry an MSH2
missense mutation (T552P in family 125), tumor anal-
ysis revealed an MSI-high phenotype. As described by
Foulkes et al. (2002), one possible approach to the anal-
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ysis of the pathogenicity of missense mutations is the
analysis of large cohorts of affected and healthy indi-
viduals. Moreover, cosegregation analysis of the alleged
mutation with the disease phenotype within extensive,
multigeneration pedigrees can provide strong support
for the pathogenicity of the missense substitution. How-
ever, definitive proof or disproof of the pathogenicity
of such mutations can be obtained only by implement-
ing functional studies. The latter have been primarily
performed in yeast (Ellison et al. 2001), although novel
protocols based on mammalian expression systems have
also been applied successfully (Nakagawa et al. 2002;
Trojan et al. 2002; see below).
In a kindred with classical HNPCC that was negative
for mutations in MSH2, MLH1, orMSH6 (family 101),
analysis of a colorectal cancer showed an MSI-high phe-
notype and loss of MSH2 protein expression by IHC,
indicating that functional impairment ofMSH2—for ex-
ample, by a promotor mutation (Shin et al. 2002) or a
splicing error due to a change within an intron—may
underlie HNPCC in this family. In another kindred with
classical HNPCC (family 158), a mutation was detected,
by MAMA, by Yan et al. (2000). By using this technique,
these authors found a splice-acceptor mutation inMSH2
that was proven hard to detect by conventional mutation
analysis (table 3) (Yan et al. 2000). One other family
negative for mutations inMSH2,MLH1, orMSH6 (fam-
ily 143) was studied byMAMA.This family did not fulfill
the Amsterdam criteria but was highly reminiscent of
HNPCC, because of the presence of multiple related tu-
mors in an affected individual and colorectal cancer in
several individuals. The index patient from this family
presented with colorectal cancer at age 56 years. Con-
version analysis showed expression of the three MMR
genes. Hence, the latter case may represent a bona fide
carrier of a genetic defect at a locus other than the major
MMR genes. Alternatively, the index patient may rep-
resent a phenocopy. This underscores the importance of
testing individuals who are most likely, on the basis of
clinical features, to carry the familial genetic defect—
namely, the presence of HNPCC-related tumors and their
age at onset (Wijnen et al. 1998b).
In total, only two mutations were found in MSH6.
One is a frameshift mutation, and the other is an in-
frame deletion of 3 nt of unknown significance (in fam-
ilies 153 and 154, respectively). Both families are char-
acterized by patients with endometrial cancer and by a
relatively late onset of colorectal cancer, in agreement
with the atypical phenotypic features associated with
MSH6 mutations (Kolodner et al. 1999; Wijnen et al.
1999; Wu et al. 1999; Wagner et al. 2001). The rela-
tively low incidence of MSH6 mutations is interesting
in view of the percentages (8% and 30% of the Am-
sterdam-positive and -negative kindreds, respectively) of
the families with HNPCC in which no mutation could
be detected. It is likely that genes like MSH6 that cause
an overlapping though distinct phenotype are respon-
sible for a small subset of the families with HNPCC
and for a larger proportion of the atypical kindreds.
The high detection rate in our study is partially due
to the screening for and identification of larger genomic
rearrangements. The latter enabled us to identify one
common ∼20-kb deletion, encompassing exons 1–6 of
theMSH2 gene, that was proven to represent a founder
mutation in the North American population. The origin
of this mutation could be traced back to the beginning
of the 19th century. Nucleotide sequence analysis of the
nine deletion breakpoints did not reveal any base pair
difference, as would be expected from a recurring re-
combination event. Also, haplotype analysis of the seven
of the nine families with HNPCC carrying the common
deletion by CA repeat markers flanking theMSH2 gene
was in agreement with the founder hypothesis. In the
majority of the cases, a region of ∼8 cM is conserved.
This is in agreement with a relatively young age of the
founder deletion. Accordingly, although the alleged an-
cestor was of German origin, we were unable to find
the same deletion in an extensive analysis of European
patients with HNPCC (Wijnen et al. 1998a) and in a
cohort of 89 German families with HNPCC (authors’
unpublished data). As confirmed by the PCR screening
of the small but clinically selected Ohio cohort, this
mutation represents 10% of the disease-causing mu-
tations among the Midwestern white families with
HNPCC. Further analyses are needed to determine the
frequency of this founder in other U.S. populations. No-
tably, screening of the MSI-positive Ohio cohort (np
, 98 of whom were MSI-high and 30 of whom were128
MSI-low) for the presence of the founder MSH2 dele-
tion failed to detect any additional carrier. The latter
finding does not affect the alleged frequency of the foun-
der mutation, since it is known that a large fraction of
the MSI-high cases represent sporadic tumors due to
hypermethylation of the MLH1 promoter. Moreover, a
large fraction of sporadic CRC is known to be MSI-
low (Halford et al. 2002). Therefore, this finding em-
phasizes the importance of clinical selection.
Seven additional genomic rearrangements were de-
tected in our cohort. Five of the genomic rearrange-
ments were in MSH2. Notably, in the case of family
177, the 13-kb deletion maps 6 kb 5′ of MSH2. Pre-
sumably, this deletion encompasses upstream regulatory
sequences, although no evidence for its true pathoge-
nicity could be demonstrated in this study. Also, in view
of the high frequency of genomic rearrangements de-
tected in the MSH2 gene in our (data not shown) (Wij-
nen et al. 1998a) and other laboratories (Charbonnier
et al. 2002), this locus may contain sequences prone to
recombination. Indeed, genomic sequences immediately
upstream of MSH2 and some of its larger introns (in-
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trons 6, 7, and 8; 13.3 kb, 15.6 kb, and 17.4 kb, re-
spectively) do contain many repetitive sequences, like
Alu and other repeats (from our own analysis by
RepeatMasker [RepeatMasker Web Server]) (Charbon-
nier et al. 2002). These repeats are known to mediate
recombination events between partially homologous se-
quences resulting in genomic deletions, insertions, in-
versions, or other more-complex rearrangements (Wag-
ner et al. 2002). On the basis of our findings, mutation
analysis must include screening for genomic rearrange-
ments, since these represent a frequent cause of disease
at the major MMR genes (in this study, 24% of the
total HNPCC burden and 50% of the cases due to
MSH2). The characterization of the breakpoints of the
most common genomic rearrangements will allow the
development of PCR-based screening protocols (present
study) to circumvent more cumbersome and time-con-
suming methods such as Southern blotting.
Overall, accurate and expert clinical selection of the
studied families greatly improves mutation detection,
especially when combined with a thorough and exten-
sive methodological approach. Thirty-four (69%) of the
Amsterdam criteria–positive families in our cohort had
two additional relatives with an HNPCC-related tumor,
exceeding the Amsterdam criteria requirements. In all
these families, an MSH2 or MLH1 mutation was de-
tected. Also, a pathogenic mutation was detected in all
families fulfilling the revised Amsterdam criteria, only
one of which was in MSH6. This indicates that the
fulfillment of the Amsterdam criteria by three patients
with colorectal cancer is not necessarily an indication
of the presence of an MSH2 or MLH1 mutation. This
is probably because of the high frequency of colorectal
cancer in the general population, often with relatively
early age at onset, and because of other forms of familial
clustering of colorectal cancer cases. The presence of
additional relatives with HNPCC-related tumors con-
siderably increases the chance of MSH2 or MLH1 mu-
tation detection. Patients with multiple HNPCC-related
tumors or with sebaceous tumors reminiscent of Muir-
Torre syndrome were observed in mutation-positive
families that did not fulfill the Amsterdam criteria. Con-
versely, we were unable to detect the disease-causing
mutation in one family with “classical” HNPCC (family
101). A colorectal tumor sample of the index patient
from this family displayed an MSI-high phenotype and
loss of MSH2 expression.
In conclusion, improved clinical selection forms the
basis of optimal mutation detection in HNPCC. Mu-
tation analysis in “classical” HNPCC should focus on
the two major MMR genes—that is,MSH2 andMLH1.
We underscore that, apart from point mutations,
genomic rearrangements strongly contribute to the
HNPCCmutation spectrum.MSI and IHC analyses will
direct further mutation detection strategies in the mu-
tation-negative families with classical HNPCC and in
the more atypical HNPCC cases. This approach has also
led to the identification of a common North American
deletion in MSH2 accounting for ∼10% of our cohort.
Genealogical, molecular, and haplotype studies showed
that this common deletion represents a North American
founder mutation that could be traced back to the 19th
century.
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